Navigation Links
"Tomorrow's Health" TV Series Showing the Life Science Industry's Quest to Save and Improve Lives, to Air on Select NBC Stations
Date:11/7/2011

SAN DIEGO, Nov. 7, 2011 /PRNewswire/ -- BIOCOM, the trade group representing Southern California's life science industry, and award-winning Phase 3 Digital have partnered to tell the biotechnology story from discovery through development. Consumers across the U.S. will soon get a glimpse into the exciting and innovative world of medical discovery that brings life-saving therapies, medical devices and diagnostics to patients around the globe. "Tomorrow's Health," a new television series created in partnership with the life sciences industry, explores some of the most exciting and promising new treatments under development.

"Tomorrow's Health" introduces viewers to patients, their doctors, and their struggle to achieve healthier lives. The program reveals the surprising truth about the challenges and obstacles biomedical researchers face in the development of cures and bringing new medicines, medical devices and diagnostics to market.

Created and produced by Phase 3 Digital, in partnership with BIOCOM, "Tomorrow's Health" will run on select NBC stations and other major network and cable channels in top media markets around the U.S. The program will feature a website and social media portals, where consumers can view episodes on demand and gain more information on companies and the featured experts.

For more information on how to be considered as a featured company, sponsorship opportunities, or other information contact Ed Personius at Phase 3 Digital, at (714) 748-0600.


'/>"/>
SOURCE BIOCOM
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China
3. Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals New Publication Series; Essential Deal Trends
4. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
5. Creabilis Raises €15M ($20M) in Series B Fundraising Round
6. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
7. SironRX Therapeutics Raises $3.4 Million Series A
8. Peloton Therapeutics Completes $18 Million Series A Financing
9. Health Diagnostic Laboratory Inc. Sponsors Lecture Series in West Palm Beach, Florida
10. Northwest Biotherapeutics Announces Series of Financing Arrangements
11. Naurex Completes $18 Million Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Windtree Therapeutics, Inc. ... focusing on developing aerosolized KL4 surfactant therapies for ... preclinical influenza study showed that aerosolized KL4 surfactant ... a well-established preclinical animal model. The Company believes ... body of evidence that supports the role of ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, Slone ... with GenePeeks. Matt is a veteran life sciences and molecular diagnostics executive ... focused on identifying inherited disease risk in future generations. In his new role, ...
(Date:2/15/2017)... Inc. (Vanda) (NASDAQ: VNDA), today announced financial and ... year ended December 31, 2016. "2016 ... continued to demonstrate strong growth in our commercial ... Mihael H. Polymeropoulos, M.D., Vanda,s President and CEO. ... milestones underscores Vanda,s commitment to bringing important new ...
(Date:2/15/2017)... ... 2017 , ... Diameter Health (Diameter) and Lantana ... in the hands of Lantana analysts. The high-performance platform of Diameter combined with ... entities – all those mining value from clinical data – to get the ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):